| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry; human; loading ...; fig 3
| Jiao Q, Liu C, Li W, Fang F, Qian Q, Zhang X. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells. Clin Exp Immunol. 2017;188:420-429 pubmed publisher |
| Chou C, Yang R, Chan L, Li C, Sun L, Lee H, et al. The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. Am J Cancer Res. 2020;10:2621-2634 pubmed |
| Wei J, Wang Y, Lee C, Truillet C, Oh D, Xu Y, et al. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020;: pubmed publisher |
| Lv J, Guo T, Qu X, Che X, Li C, Wang S, et al. PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR. Front Oncol. 2020;10:1067 pubmed publisher |
| Pei X, Yao H, Shen L, Yang Y, Lu L, Xiao J, et al. α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway. Eur J Pharmacol. 2020;883:173355 pubmed publisher |
| Li Q, Chen Q, Klauser P, Li M, Zheng F, Wang N, et al. Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics. Cell. 2020;182:85-97.e16 pubmed publisher |
| Komura N, Mabuchi S, Shimura K, Yokoi E, Kozasa K, Kuroda H, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer Immunol Immunother. 2020;: pubmed publisher |
| Yan Y, Zheng L, Du Q, Yan B, Geller D. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother. 2020;: pubmed publisher |
| Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11:309 pubmed publisher |
| Yang K, Zhou J, Chen Y, Chen L, Zhang P, Ma L, et al. Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma. Int Immunopharmacol. 2020;84:106507 pubmed publisher |
| Duan M, Fang M, Wang C, Wang H, Li M. LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis. Cancer Manag Res. 2020;12:2141-2154 pubmed publisher |
| Tay W, Fang Y, Beh S, Liu Y, Hsu L, Yen C, et al. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro. Int J Mol Sci. 2020;21: pubmed publisher |
| Zheng S, Liu Q, Liu T, Yang L, Zhang Q, Shen T, et al. NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma. Biochem Biophys Res Commun. 2020;526:29-34 pubmed publisher |
| Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, et al. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. Cancer Cell. 2020;37:324-339.e8 pubmed publisher |
| Qin T, Xia J, Liu S, Wang J, Liu H, Zhang Y, et al. Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients. Thorac Cancer. 2020;11:1139-1148 pubmed publisher |
| Li X, Xu Z, Cui G, Yu L, Zhang X. BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes. Onco Targets Ther. 2020;13:215-224 pubmed publisher |
| Hu M, Yang J, Qu L, Deng X, Duan Z, Fu R, et al. Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma. Food Funct. 2020;11:456-471 pubmed publisher |
| Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, et al. Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin. Front Pharmacol. 2019;10:1658 pubmed publisher |
| Wen B, Zhao L, Wang Y, Qiu C, Xu Z, Huang K, et al. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1). Prep Biochem Biotechnol. 2019;:1-8 pubmed publisher |
| Chen M, Gilbert N, Liu H. Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway. Reprod Biol Endocrinol. 2019;17:86 pubmed publisher |
| Wang Y, Li J, Ba H, Wang K, Wen X, Li D, et al. Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma. Front Oncol. 2019;9:857 pubmed publisher |
| Zhao Y, Wang X, Wu W, Long H, Huang J, Wang Z, et al. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells. Biochem Biophys Res Commun. 2019;517:201-209 pubmed publisher |
| Guo C, Zhao H, Wang Y, Bai S, Yang Z, Wei F, et al. Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma. Front Oncol. 2019;9:439 pubmed publisher |
| Li P, Huang T, Zou Q, Liu D, Wang Y, Tan X, et al. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway. J Immunol. 2019;202:3065-3075 pubmed publisher |
| Liu S, Qin T, Jia Y, Li K. PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival. Front Oncol. 2019;9:189 pubmed publisher |
| Wang T, Chen S, Wang X, Huang Y, Qiu J, Fei Y, et al. Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection. Antiviral Res. 2019;166:1-10 pubmed publisher |
| Xu Y, Cui G, Jiang Z, Li N, Zhang X. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett. 2019;17:2960-2968 pubmed publisher |
| Xiong W, Deng H, Huang C, Zen C, Jian C, Ye K, et al. MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity. Biochim Biophys Acta Mol Basis Dis. 2019;1865:454-463 pubmed publisher |
| Liu C, Zhang H, Zhi L, Jin P, Zhao L, Li T, et al. CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP. Inflammation. 2019;42:135-144 pubmed publisher |
| Amoils M, Kim J, Lee C, Sunwoo J, Colevas A, Aasi S, et al. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2019;160:93-99 pubmed publisher |
| Jin J, Si J, Liu Y, Wang H, Ni R, Wang J. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respir Res. 2018;19:197 pubmed publisher |
| Guo J, Qu H, Shan T, Chen Y, Chen Y, Xia J. Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity. Mol Cells. 2018;41:653-664 pubmed publisher |
| Zhen J, Chen W. MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice. Biomed Pharmacother. 2018;97:1479-1485 pubmed publisher |
| Hsu J, Xia W, Hsu Y, Chan L, Yu W, Cha J, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9:1908 pubmed publisher |
| Cannon J, Russell J, Kim J, Chang A. A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery. JAAD Case Rep. 2018;4:248-250 pubmed publisher |
| Dai X, Pi G, Yang S, Chen G, Liu L, Dong H. Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma. Transl Oncol. 2018;11:559-566 pubmed publisher |
| Dai X, Xue J, Hu J, Yang S, Chen G, Lai P, et al. Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma. Transl Oncol. 2017;10:511-517 pubmed publisher |
| Chang J, Zhu G, Cheung C, Li S, Kim J, Chang A. Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. JAMA Dermatol. 2017;153:285-290 pubmed publisher |
| Pi G, He H, Bi J, Li Y, Li Y, Zhang Y, et al. Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report. Medicine (Baltimore). 2016;95:e5077 pubmed |
| Song Z, Yu X, Cheng G, Zhang Y. Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma. J Transl Med. 2016;14:188 pubmed publisher |
